GlassScriptPhysician profile
Tariq Marroush
NPI 1134506934
$6,743.56
in general payments reported to CMS, 2019-2025
23 companies · $500 in 2025
The $500 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $409 · 2021: $1,255 · 2022: $1,238 · 2023: $760 · 2024: $1,520 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,989.85 | 2019-2025 | Dragonfly Opstar, Xience Skypoint, Mitraclip |
| Boston Scientific Corporation | $560.94 | 2021-2023 | |
| Medtronic, INC. | $505.86 | 2022-2024 | Symplicity G3, Ffrangio, Hawkone |
| Astrazeneca Pharmaceuticals LP | $417.62 | 2019-2021 | |
| Inari Medical, INC. | $375.90 | 2021-2022 | |
| Shockwave Medical, INC | $367.35 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $354.96 | 2021-2025 | Repatha, Repatha |
| Cvrx, INC. | $295.38 | 2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $269.62 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $240.89 | 2019-2022 | |
| Edwards Lifesciences Corporation | $210.63 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Impulse Dynamics (USA) INC. | $197.07 | 2023-2024 | Optimizer, Optimizer |
| Novo Nordisk INC | $179.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $170.84 | 2019-2025 | |
| Pfizer INC. | $135.27 | 2019-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2024 | Camzyos |
| Cardiva Medical, INC. | $101.83 | 2022 | |
| Gilead Sciences, INC. | $92.76 | 2019 | |
| Bard Peripheral Vascular, INC. | $49.46 | 2023-2025 | Venclose Maven Catheter |
| Terumo Medical Corporation | $42.94 | 2021 | |
| Alnylam Pharmaceuticals INC. | $33.38 | 2025 | Amvuttra |
| Philips North America LLC | $15.49 | 2022 | |
| Cardiovascular Systems INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Marroush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.